Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7101 - 7125 of 9861 in total
SAR405838 has been used in trials studying the treatment of Neoplasm Malignant.
Investigational
Matched Iupac: … (2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-N-[(1r,4r)-4-hydroxycyclohexyl ... ]-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide …
Sch 486757 has been used in trials studying the treatment of Cough.
Investigational
Matched Iupac: … (1R,3R,5S)-8-[bis(2-chlorophenyl)methyl]-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-3-ol …
ACT-451840 has been used in trials studying Malaria.
Investigational
Matched Iupac: … (2E)-N-{[4-(4-acetylpiperazin-1-yl)phenyl]methyl}-3-(4-tert-butylphenyl)-N-[(2S)-1-{4-[(4-cyanophenyl ... )methyl]piperazin-1-yl}-1-oxo-3-phenylpropan-2-yl]prop-2-enamide …
BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).
Investigational
Matched Iupac: … (2R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-[4-(morpholin-4-yl)piperidin-1-yl]-1-oxopropan-2-yl 4-(2-oxo- ... 2,3,4,5-tetrahydro-1H-1,3-benzodiazepin-3-yl)piperidine-1-carboxylate …
OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
Investigational
Matched Description: … adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Investigational
Matched Name: … )-2,2,4-Trimethylpyrrolidin-1-Yl]Pyridin-3-Yl]Carbonyl})Azanide ... Potassium (Benzenesulfonyl)({[6-(3-{2-[1-(Trifluoromethyl)Cyclopropyl]Ethoxy}-1H-Pyrazol-1-Yl)-2-[(4S …
Matched Iupac: … [(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboximidate ... potassium (Z)-N-(benzenesulfonyl)-6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2- …
Experimental
Matched Name: … 1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID …
Matched Iupac: … 3-[(2R)-2-(dihydroxyboranyl)-2-acetamidoethyl]-2-hydroxybenzoic acid …
Experimental
Matched Name: … 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol …
Matched Iupac: … (1R)-1-{4-[(9aS)-octahydro-1H-pyrido[1,2-a]pyrazin-2-yl]phenyl}-2-phenyl-1,2,3,4-tetrahydroisoquinolin …
Experimental
Matched Name: … 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine …
Matched Iupac: … 1-(2,6-difluorobenzenesulfonyl)-4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)piperazine …
Investigational
Experimental
Experimental
Matched Name: … 3-Amino-3-Oxopropanoic Acid …
Angelica sinensis root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Dazodalibep is under investigation in clinical trial NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity).
Investigational
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Iupac: … sulfooxy)methyl]oxan-3-yl]oxy}-4,5-dimethoxy-3-{[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-[(sulfooxy)methyl ... (2S,3S,4S,5R,6R)-6-{[(2R,3R,4S,5R,6R)-6-{[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-{[(2R,3R,4S,5R,6S ... )-6-methoxy-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-bis(sulfooxy)-2-[( …
CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.
Investigational
Matched Iupac: … 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide …
Recombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.
Investigational
Experimental
Matched Name: … (2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid …
Matched Iupac: … (2S)-2-[1-(2,4-dichlorophenyl)-N-{[3-(trifluoromethyl)phenyl]methyl}formamido]-3-phenylpropanoic acid …
Experimental
Matched Name: … N-{3-[(E)-(tert-butoxyimino)methyl]-4-chlorophenyl}-2-methylfuran-3-carbimidothioic acid …
Matched Iupac: … N-{3-[(1E)-[(tert-butoxy)imino]methyl]-4-chlorophenyl}-2-methylfuran-3-carbothioamide …
Experimental
Matched Name: … 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE …
Matched Iupac: … 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-1,3-benzodiazol-1-yl)thiophene-2-carboxamide …
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Iupac: … (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane …
Gallopamil has been used in trials studying the treatment of Asthma.
Investigational
Matched Iupac: … 5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)-2-(3,4,5-trimethoxyphenyl)pentanenitrile …
Matched Salts cas: … 16662-46-7
Experimental
Matched Iupac: … (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-(phosphonooxy)hexanoic acid …
Experimental
Matched Iupac: … (2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid …
Displaying drugs 7101 - 7125 of 9861 in total